- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
AstraZeneca AB v. Mylan Pharms. Inc.
Because Delaware was an improper venue for defendant Mylan, and defendant 3M demonstrated that various factors weighed in favor of a transfer, the case was transferred to the Northern District of West Virginia.
October 18, 2019
Case Name: AstraZeneca AB v. Mylan Pharms. Inc., No. 18-1562-CFC, 2019 U.S. Dist. LEXIS 180264 (D. Del. Oct. 18, 2019) (Connolly, J.)
Drug Product and Patent(s)-in-Suit: Symbicort® (budesonide/formoterol fumarate dihydrate); U.S. Patents Nos. 7,759,328 (“the ’328 patent”), 8,143,239 (“the ’239 patent”), 8,575,137 (“the ’137 patent”), and 7,967,011 (“the ’011 patent”)
Nature of the Case and Issue(s) Presented: AstraZeneca sued various Mylan entities on Oct. 11, 2018. On Dec. 19, 2018, AstraZeneca filed a first amended complaint, adding 3M Company (“3M”) as a defendant. On Mar. 14, 2019, certain of the Mylan defendants were dismissed by stipulation and order. AstraZeneca was the holder of the NDA that covered Symbicort. Mylan was the sole holder of the ANDA seeking approval to make and sell a generic version of Symbicort. According to Mylan, 3M would have manufactured the ANDA product for Mylan but would not have been involved in any marketing, promotion, distribution or sale of Mylan’s ANDA product.
Mylan moved to dismiss under Fed. R. Civ. P. 12(b)(3) for improper venue pursuant to 28 U.S. C. § 1400(b) and 3M moved to transfer this case to the Northern District of West Virginia pursuant to 28 U.S.C. § 1404(a), or in the alternative, to dismiss the claims against it under Fed. R. Civ. P. 12(b)(7) for failure to join a party under Fed. R. Civ. P. 19. The court denied Mylan’s motion to dismiss and granted-in-part and denied-in-part 3M’s motion to dismiss or transfer venue.
Why the Case Was Transferred to the N.D.W.V.: Turning first to Mylan’s motion, it was undisputed that (i) Mylan was a West Virginia corporation and did not “reside” in Delaware under § 1400(b); and (ii) Mylan did not have a regular and established place of business in Delaware. But AstraZeneca argued that venue was proper in Delaware for 3M because 3M was a Delaware corporation and therefore venue was also proper as to Mylan because: (i) Mylan was 3M’s successor-in-interest in the ANDA; (ii) Mylan was 3M’s agent; and (iii) Mylan and 3M had attempted to manipulate venue by devising a scheme through which they sought to deprive AstraZeneca of the ability to sue the party who submitted the ANDA in the district where it and AstraZeneca resided. The court disposed of all three arguments. It found that while Mylan accepted the responsibility to perform 3M’s duties under the ANDA, Mylan did not assume 3M’s place of residency in doing so. AstraZeneca’s pure agency argument failed because AstraZeneca had not established that the court should impute the residency of 3M to Mylan based on an agency relationship between 3M and Mylan. Finally, although Mylan’s communications with AstraZeneca could reasonably be described as deceptive and even manipulative insofar as they hid from AstraZeneca the role 3M played in the ANDA process, Mylan did nothing that deprived AstraZeneca of the ability to sue 3M—the party that submitted the ANDA—in Delaware. Thus, Delaware was an improper venue for Mylan. But in lieu of dismissal, the court transferred AstraZeneca’s claims against Mylan to the Northern District of West Virginia.
Turning next to 3M’s motion to transfer, the court weighed the various Jumara factors underlying its decision. Of the twelve Jumara factors, seven factors were neutral, one factor weighed against transfer, and four factors—defendant’s forum preference, the convenience of the parties as indicated by their relative physical and financial condition, practical considerations, and relative administrative difficulty due to court congestion—weighed in favor of transfer. Therefore, 3M’s motion to dismiss for failure to join Mylan as a party was rendered moot.
Related Professionals
Christopher A. Pinahs
Partner
Haroon N. Mian
Associate
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.